Bausch Health (BHC): Analyst Downgrades Price Target to $7, Yet Offers 37% Upside Potential

Tuesday, Mar 31, 2026 7:37 am ET1min read
BHC--

Bausch Health Companies Inc. (NYSE:BHC) is a small-cap drug manufacturing stock that has been identified as one of the 7 best to buy according to hedge funds. Despite a reduced price target from Barclays, the stock has an adjusted upside potential of almost 37%. The company's fourth quarter report showed year-on-year growth in key financial metrics, and CEO Thomas Appio attributed this to commercial and operational strength. Bausch Health engages in the development and sale of a range of items for the healthcare industry across various segments.

Bausch Health (BHC): Analyst Downgrades Price Target to $7, Yet Offers 37% Upside Potential

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet